Table 1.

Association between the m⁶A contents and the clinicopathological characteristics in BC patients

Variable	No. of patients	Peripheral blood m6A contents mean±SD (%)	p-value
Age (yr)
< 50	22	0.141±0.070	0.795
≥ 50	40	0.141±0.080
TNM
0	6	0.085±0.020	0.968
I	10	0.166±0.096
II	31	0.152±0.084
III	6	0.143±0.021
IV	2	0.190±0.042
Stage
0	6	0.085±0.020	0.003
I–IV	49	0.155±0.080
T category
Tis	6	0.085±0.020	0.129
T1–T2	41	0.155±0.086
T3–T4	6	0.142±0.029
N category
N0	35	0.135±0.078	0.078
N1	15	0.171±0.085
N2–N3	3	0.143±0.031
M category
M0	53	0.146±0.079	0.174
M1	2	0.190±0.042
TNBC
Yes	8	0.150±0.068	0.72
No	47	0.147±0.081
AFP (ng/mL)
< 6	59	0.142±0.077	0.735
≥ 6	3	0.127±0.076
CEA (ng/mL)
< 5	54	0.146±0.079	0.213
≥ 5	8	0.108±0.039
CA125 (IU/mL)
< 35	55	0.141±0.079	0.649
≥ 35	7	0.140±0.049
CA153 (IU/mL)
< 25	58	0.141±0.077	0.985
≥ 25	4	0.143±0.078

AFP, α-fetoprotein; BC, breast cancer; CA125, cancer antigen 125; CA153, carbohydrate antigen 153; CEA, carcinoembryonic antigen; m⁶A, N6-methyladenosine; SD, standard deviation; TNBC, triple-negative breast cancer.